The role of DPP-4 inhibitors in modern diabetes therapy

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Karhu_HU
dc.contributor.authorCholia, Jeevan Singh
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2021-05-24T14:11:15Z
dc.date.available2021-05-24T14:11:15Z
dc.date.created2021-05-20
dc.description.abstractDiabetes mellitus is now a global pandemic, with an estimated 463 million sufferers worldwide according to the International Diabetes Federation and is characterised by its chronic and complex nature requiring constant medical attention. Due to the varied and multifaceted pathophysiology, a number of different therapeutic options have been developed over the years for type 2 diabetes, including the inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4). These DPP-4 inhibitors or gliptins are able to prevent the degradation of the incretin hormones, glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which prolongs the glucose-mediated insulin secretory action of the incretins (i.e. the incretin effect). The five main gliptin available on the market include: sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin, these are taken orally and have a glycaemic efficacy and safety characteristics which are akin to one another. They do however differ in terms of: potency, target selectivity, elimination half-life, oral bioavailability, protein binding, metabolism, excretion routes and dosage adjustment with regards to renal and hepatic insufficiency. DPP-4 inhibitors as a whole have been reported to be generally well tolerated and with a low risk of side effects.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent37hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/310162
dc.language.isoenhu_HU
dc.subjectDiabeteshu_HU
dc.subjectDPP-4 inhibitorshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titleThe role of DPP-4 inhibitors in modern diabetes therapyhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)